Peak Pharmaceuticals was awarded the patent certificate of the invention of the slow-release tablets of aceclofenac and its preparation methods.


Release time:

2012-08-29

On August 19, the aceclofenac sustained-release tablets and their preparation methods of Jianfeng Pharmaceutical were reviewed by the the People's Republic of China Intellectual Property Office in accordance with the the People's Republic of China Patent Law, and the patent right was granted and the invention patent certificate was obtained. The patent right period is 20 years.
Aceclofenac sustained-release tablets as non-steroidal anti-inflammatory drugs, its mechanism of action is mainly through the inhibition of cyclooxygenase activity, so that prostaglandin synthesis is reduced, can play a variety of pharmacological effects in the lesion, when a powerful anti-inflammatory, antipyretic, analgesic. This variety is a new type of slow-release preparation, currently for the domestic exclusive dosage form, exclusive listing, with a new drug certificate.
The market prospect of aceclofenac sustained-release tablets is promising. Compared with the current production of anti-inflammatory and analgesic drugs in China, such as aspirin, ibuprofen, naproxen, indomethacin, diclofenac, etc., not only do these products have strong gastrointestinal irritation, but can seriously cause adverse reactions such as upper gastrointestinal bleeding, ulcer or perforation, on the contrary, the drug has the characteristics of definite curative effect, good tolerance and relatively safe use. Aceclofenac sustained-release tablets taken once a day can effectively reduce the fluctuation of blood drug concentration, and its effective blood drug concentration is maintained for a long time, which further reduces the gastrointestinal irritation response and is more easily accepted by patients.
The pharmaceutical company has put into production of this variety in May, which is expected to bring considerable economic benefits to the company.